Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03618030 · ClinicalTrials.gov registry record · Phase 3
PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 3 study of ADHD, sponsored by Purdue Pharma, Canada.
- Completed
- Registry status
- Phase 3
- Development phase
- 288
- Enrollment target
- 8
- Study locations
NCT03618030 is a Phase 3 study of ADHD that has completed, run by Purdue Pharma, Canada. The registered enrollment target is 288 participants, above the 186-participant average among 75 other ADHD trials with a reported enrollment target (55% higher). The trial reports 8 study locations across 6 states.
The verdict
NCT03618030, a Phase 3 study of ADHD, has completed, sponsored by Purdue Pharma, Canada.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 288 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a randomized, double-blind, parallel group, placebo-controlled, dose optimized, phase 3 study to evaluate the safety and efficacy of PRC-063 in the treatment of ADHD in adults
Conditions Studied
Interventions
- DRUG Placebo oral capsules
- DRUG PRC-063 oral capsules
Study Locations (8)
Florida
- Meridien Research Inc. - Bradenton
- Meridien Research - Lakeland
- Meridien Research Inc. - Maitland
Massachusetts
- South Shore Psychiatric Services - Hingham
Nevada
- Center for Psychiatry and Behavioral Medicine - Las Vegas
North Carolina
- Center for Psychiatry and Behavioral Medicine - Durham
Pennsylvania
- Penn State Health Milton S. Hershey Medical Center - Hershey
Texas
- Bayou City Research - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 288 participants |
| Start Date | 2018-08-21 |
| Est. Completion | 2019-07-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03618030
The ClinicalTrials.gov registry entry for NCT03618030 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 288 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 186-participant average among 75 other ADHD trials with a reported enrollment target (55% higher). The listed sponsor is Purdue Pharma, Canada, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with ADHD appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral capsules is the first listed.
NCT03618030 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Florida, Massachusetts, Nevada.
Frequently Asked Questions
What is clinical trial NCT03618030 about?
NCT03618030 is a clinical study titled "PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)". This is a randomized, double-blind, parallel group, placebo-controlled, dose optimized, phase 3 study to evaluate the safety and efficacy of PRC-063 in the treatment of ADHD in adults
What is the current status of trial NCT03618030?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 288 participants. The study started on 2018-08-21. Estimated completion is 2019-07-05.
What conditions does trial NCT03618030 study?
This clinical trial studies the following conditions: ADHD.
What interventions are being tested in trial NCT03618030?
The interventions under investigation include: Placebo oral capsules (DRUG), PRC-063 oral capsules (DRUG).
Who is sponsoring clinical trial NCT03618030?
This trial is sponsored by Purdue Pharma, Canada, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03618030 being conducted?
This trial has 8 study locations across Florida, Massachusetts, Nevada, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ADHD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
RECRUITING · Phase 3
-
Treating Parents with ADHD and Their Young Children Via Telehealth: a Hybrid Type I Effectiveness-Implementation Trial
ACTIVE NOT RECRUITING · Phase 3
-
Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD)
COMPLETED · Phase 3
-
Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD
COMPLETED · Phase 3
-
Study to Assess Satisfaction With Modafinil Treatment in Children and Adolescents With ADHD
COMPLETED · Phase 3
-
Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.